ConductScience.org, home

Trial · NCT07913451

Integrating Sport-Specific Comprehensive Training to Upscale Performance in Women and Girls

NCT07913451, Not applicable, Not yet recruiting, Sport Injury Prevention Research Centre

3 sourcestrials-2026-11-12-0.4.0

Download JSON
Cite this record

ConductScience Library. Integrating Sport-Specific Comprehensive Training to Upscale Performance in Women and Girls. Trials, record NCT07913451. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07913451

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
Integrating Sport-Specific Comprehensive Training to Upscale Performance in Women and Girls
NCT number
NCT07913451
Status
Not yet recruiting
Phases
Not applicable
Enrollment
250 participants, estimated
Lead sponsor
Sport Injury Prevention Research Centre
Conditions
Sport Injuries, Performance in Sport
Interventions
Typical training, SUPERGirl training
First posted
2026-11-03
Last updated
2026-11-03

Source ClinicalTrials.gov

Registered outcomes31

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryKnee Extensor Explosive StrengthDay 1, 6 weeks, 12 weeks, end of season (approximately 24 weeks)
Knee extensor explosive strength will be assessed using a rigid custom-built dynamometer mounted with a load cell sampling at 1000 Hz. Participants will be positioned in the seat with the centre of the knee joint aligned with the axis of rotation. The backplate will be adjusted to maintain a hip flexion angle of 80° relative to full extension, and the load cell connected to a shank plate will be adjusted to the same position for all participants, approximately 2.5 cm above the lateral malleolus. Testing will be conducted at 80° of knee flexion relative to full extension, verified using a goniometer. Velcro straps will be secured across the shoulders, waist, and thigh to minimize participant movement. The participant's shank will be strapped to an ankle attachment with a Velcro strap. The moment arm, defined as the distance from the knee joint centre to the contact point with the ankle attachment, will be measured using a measuring tape. The seat position and moment arm from the centre
PrimaryLower Limb Explosive StrengthDay 1, 6 weeks, 12 weeks, end of season (approximately 24 weeks)
Leg Press Testing: Lower-limb strength will be assessed using robotic servomotor leg press maximal voluntary contraction testing. Participants will complete three MVCs of isometric, concentric, and eccentric leg press force testing using a robotic servomotor leg press. This will include three MVCs of isokinetic eccentric and concentric leg press actions performed at a constant speed of 0.2 m·s-¹. Each strength test will be separated by a 3-5-minute rest period, and each repetition will be separated by a 10-second rest interval. Strong verbal encouragement will be provided throughout the testing session by a certified exercise physiologist. MVC leg extensor strength will be measured using a robotic servomotor leg press device sampling at 200 Hz. Three repetitions of MVC eccentric and concentric leg press movements will be performed between 100° and 10° of knee flexion at a constant speed of 0.2 m·s-¹, with a 0.5-second pause between the concentric and eccentric movement phases. Servomo
PrimaryCountermovement Jump Stretch-Shortening Cycle MechanicsDay 1, 6 weeks, 12 weeks, end of season (approximately 24 weeks)
Countermovement jump stretch-shortening cycle mechanics will be assessed using a dual force plate system sampling at 1000 Hz. Participants will be instructed to keep their hands firmly placed on their hips during unloaded countermovement jump testing to isolate the contributions of the lower limbs to vertical jump height and body centre of mass power and work production. During loaded countermovement jump testing, participants will hold the hexagonal trap bar and will be instructed to keep their arms straight throughout the entire jumping procedure. Participants will freely determine all other aspects of jump strategy, including their preferred depth, defined as downward body centre of mass displacement. The vertical ground reaction forces of the right and left leg will be measured synchronously and stored for later offline analysis. Body centre of mass vertical velocity will be obtained by time integration of the instantaneous acceleration signal from the sum of the left and right ve
PrimaryMaximal Sprint SpeedDay 1, 6 weeks, 12 weeks, end of season (approximately 24 weeks)
Maximal sprint speed (vMax) will be assessed using a 40 m linear sprint with electronic timing gates positioned perpendicular to a flat, non-slip sprinting surface at 10, 20, 30, and 40 m. Over-ground sprint testing across distances of 5-40 m is commonly used to assess sprint ability in youth athletes. Timing gates will be set at a standardized height of 1.0 m from the ground and positioned 1.22 m apart, corresponding to the approximate width of a standard track lane. Participants will begin from a stationary two-point standing start with the front foot positioned at the 0 m start line. Participants will start when ready and will be instructed to sprint maximally through the 40 m finish line without decelerating before the final timing gate. Each athlete will complete three maximal sprint trials, with 3-5 min of passive recovery between trials. Split times will be recorded at 10, 20, 30, and 40 m. vMax will be calculated from the fastest 10 m split recorded between timing gates, using
PrimaryMaximal Aerobic SpeedDay 1, 6 weeks, 12 weeks, end of season (approximately 24 weeks)
Maximal aerobic speed (vMAS) was estimated using a 5-minute maximal running time trial performed on an indoor track. Athletes were instructed to cover the greatest possible distance in 5 minutes using an even maximal pacing strategy. Total distance covered was recorded to the nearest meter. The 5-minute running field test was selected because it provides a practical group-administered estimate of vMAS and has demonstrated strong agreement with treadmill-derived vMAS, and the test has also demonstrated strong test-retest reliability in trained men and women.
Primary5-10-5 Change of Direction TestDay 1, 6 weeks, 12 weeks, end of season (approximately 24 weeks)
Change-of-direction speed will be assessed using the standardized 5-10-5 shuttle test. The course consisted of three parallel lines positioned in a straight line, with the centre line serving as the start/finish line and two turn lines positioned 5 yards (4.57 m) to the left and right of centre on a flat, dry, non-slip surface with sufficient space beyond each turn line. This produced a total running distance of 20 yards (18.28 m): 5 yards to the first turn line, 10 yards (9.14 m) to the opposite turn line, and 5 yards back through the finish. Electronic timing gates were positioned at the centre start/finish line, perpendicular to the running direction. Timing gates were set at a standardized height of 1.0 m and positioned consistently for all athletes and across all testing sessions.
PrimaryFeasibility - recruitmentFrom enrolment to the end of the stud (approx 24 weeks)Number of participants recruited
PrimaryFeasibility - retention rateFrom enrolment to the end of the stud (approx 24 weeks)Number of participants completing the trial divided by the total number of participants recruited
PrimaryFeasibility - adverse eventsFrom enrolment to the end of the stud (approx 24 weeks)Number of adverse events
PrimaryFeasibility - barriers and facilitatorsFrom enrolment to the end of the stud (approx 24 weeks)Barriers and facilitators to the protocol as described by the participants and physiotherapists

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Source

Release
trials-2026-11-12-0.4.0
Release manifest SHA-256
0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
Registry capture
2026-11-12
Results copy, AACT
2026-03-23
NIH clinical studies file
2026-11-13

Source ClinicalTrials.gov

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT07913451

GET https://conductscience.org/api/trials/v1/NCT07913451/registered?page=2